Welcome to our dedicated page for Twist Bioscience Corporation news (Ticker: TWST), a resource for investors and traders seeking the latest updates and insights on Twist Bioscience Corporation stock.
Twist Bioscience Corporation, symbol TWST, stands at the forefront of synthetic biology with an innovative approach to DNA synthesis. The company's core expertise lies in developing a proprietary semiconductor-based synthetic DNA manufacturing process. This process utilizes a unique 10,000-well silicon platform, markedly different from the traditional 96-well plastic plates. This advanced platform enables the production of synthetic biology tools, such as oligonucleotides, genes, pathways, chassis, and genomes, in a more efficient, cost-effective, and high-throughput manner.
The implications of Twist Bioscience's technology are profound, offering the potential to revolutionize various fields. By synthesizing DNA on silicon, the company overcomes existing production inefficiencies, ensuring rapid and high-quality DNA synthesis. This capability is crucial for accelerating developments in personalized medicine, sustainable chemical production, agricultural improvements, in vivo diagnostics, biodetection, and even data storage.
Based primarily in the United States, Twist Bioscience derives the majority of its revenue from its home market. The company's strategic partnerships and ongoing projects reflect its commitment to pioneering advancements in synthetic biology. Having positioned itself as a leader in the field, Twist Bioscience continues to support researchers and industries by providing high-quality synthetic DNA rapidly, enabling them to seize emerging opportunities.
For more information, please visit Twist Bioscience.
Twist Bioscience (NASDAQ: TWST) has announced the promotion of Tracey Mullen to Senior Vice President of Operations and Nimisha Srivastava to Senior Vice President of Research and Development. This follows the departure of Patrick Weiss from his role as Chief Operating Officer to a strategic advisor position, effective April 21, 2022. Mullen brings extensive experience from her previous role as CEO of Abveris, while Srivastava has been pivotal in automating laboratory processes since joining Twist in 2014. The company continues its growth trajectory in synthetic biology.
Twist Bioscience Corporation (NASDAQ: TWST) will release its financial results for Q2 fiscal 2022, ending March 31, 2022, on May 5, 2022, after market close. A conference call for analysts and investors is scheduled for 4:30 p.m. ET to discuss these results and provide a business update. The press release will be available on their website ahead of the call. Twist specializes in synthetic DNA production, utilizing a unique silicon-based technology to manufacture synthetic DNA products for various industries, including healthcare and agriculture.
Twist Bioscience (NASDAQ: TWST) and MediSix Therapeutics have announced a collaboration to discover novel antibodies against five undisclosed targets. Twist will utilize its proprietary Library of Libraries for antibody discovery, while MediSix will develop CAR T-cell therapies for T-cell malignancies and autoimmune diseases. Twist is set to receive an upfront payment and may earn milestone payments and royalties on future sales. This partnership aims to address challenges in treating T-cell cancers and expands Twist's global footprint, particularly in the Asia Pacific region.
Twist Bioscience Corporation (NASDAQ: TWST) and Ginkgo Bioworks (NYSE: DNA) announced a new four-year supply agreement, enhancing their collaboration in synthetic biology. This agreement marks an increase in Ginkgo's commitments to purchase synthetic DNA from Twist to support its growth across various industries, including vaccine manufacturing and agriculture. The partnership builds on a previous agreement from 2017, highlighting a significant order of approximately one billion base pairs of synthetic DNA.
Twist Bioscience Corporation (NASDAQ: TWST) has launched synthetic RNA positive controls for SARS-CoV-2, encapsulated in proprietary stainless steel minicapsules from Imagene SA. These minicapsules provide a stable, cost-effective solution for shipping and storing fragile RNA at room temperature, overcoming cold chain limitations. This product aims to facilitate COVID-19 monitoring in regions lacking adequate storage facilities. The launch builds on a 2019 partnership with Imagene, enhancing Twist's capabilities in supplying stable RNA and DNA products globally.
Twist Bioscience (NASDAQ: TWST) has entered into an antibody discovery agreement with Kriya Therapeutics, focusing on delivering antibodies via adeno-associated viral gene therapy for oncology applications. This partnership aims to leverage Twist's advanced antibody libraries and Kriya's vector engineering platform. The collaboration seeks to enhance the precision of antibody delivery for cancer treatment and potentially expedite the development of novel gene therapies, thereby providing therapeutic benefits where they are most needed.
Twist Bioscience (NASDAQ: TWST) has joined the Digital Preservation Coalition’s Supporter Program, facilitating collaboration between members on digital content preservation. This program emphasizes the importance of long-term digital data storage solutions. CEO Emily M. Leproust expressed enthusiasm for engaging with members to refine their Century Archive DNA data storage solution. The DPC aims to address challenges faced by organizations storing valuable digital assets. This partnership may enhance Twist's position in the emerging DNA data storage market.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience (NASDAQ: TWST) announced that CEO Emily M. Leproust, Ph.D., will present at several upcoming virtual investor conferences. These include the Truist Securities AI Symposium on March 1 at 9:00 a.m. ET and the Cowen 42nd Annual Health Care Conference on March 7, featuring a fireside chat at 2:10 p.m. ET and a Synthetic Biology Enabling Technologies Panel at 10:30 a.m. ET. The Cowen presentations will be webcast live, with replays available for 30 days post-event. Twist specializes in high-quality synthetic DNA products and applications across various industries.
Twist Bioscience Corporation (NASDAQ: TWST) has completed its upsized public offering of 5,227,272 shares at $55.00 each, raising approximately $269.4 million after costs. This move follows the full exercise of the underwriters' option to purchase an additional 681,818 shares. The proceeds will be allocated towards expanding R&D in pharmaceutical biologics, DNA data storage, and Next-Generation Sequencing (NGS) operations, as well as general corporate purposes and strategic investments.
FAQ
What is the current stock price of Twist Bioscience Corporation (TWST)?
What is the market cap of Twist Bioscience Corporation (TWST)?
What does Twist Bioscience Corporation do?
How does Twist Bioscience's technology differ from traditional methods?
What are some applications of Twist Bioscience's synthetic DNA?
Where does Twist Bioscience generate most of its revenue?
How does Twist Bioscience contribute to personalized medicine?
What is the significance of using silicon in DNA synthesis?
Can Twist Bioscience's technology be used in agriculture?
What ongoing projects does Twist Bioscience have?
How does Twist Bioscience's platform support researchers?
Where can I find more information about Twist Bioscience?
